• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

硼替佐米诱导的自主神经病变继发肠穿孔

Intestinal Perforation Secondary to Bortezomib-Induced Autonomic Neuropathy.

作者信息

Sánchez Salas Jose Antonio, Moreno Belmonte Maria Jose, Poveda García Andrea, Ruiz Ruiz Estela, Soler Espejo Eva, Cabanas Perianes Valentin, García Hernandez Ana María

机构信息

Department of Hematology Virgen de la Arrixaca University Hospital Murcia Spain.

出版信息

Clin Case Rep. 2025 Apr 1;13(4):e70340. doi: 10.1002/ccr3.70340. eCollection 2025 Apr.

DOI:10.1002/ccr3.70340
PMID:40171013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11959410/
Abstract

It is essential to evaluate both the patient's prior conditions and the severity of the current clinical presentation when deciding on BTZ toxicity management. It seems prudent to consider the permanent discontinuation of the drug in patients who have experienced at least grade 3 intestinal neuropathy and have structural abnormalities or other risk factors for intestinal perforation. NCT03710603.

摘要

在决定硼替佐米（BTZ）毒性管理时，评估患者既往病情和当前临床表现的严重程度至关重要。对于经历过至少3级肠道神经病变且存在肠道穿孔结构异常或其他风险因素的患者，考虑永久停用该药物似乎是谨慎的做法。NCT03710603。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dea/11959410/fdffab281c37/CCR3-13-e70340-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dea/11959410/7fc8e39724e6/CCR3-13-e70340-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dea/11959410/fdffab281c37/CCR3-13-e70340-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dea/11959410/7fc8e39724e6/CCR3-13-e70340-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dea/11959410/fdffab281c37/CCR3-13-e70340-g003.jpg

相似文献

1
Intestinal Perforation Secondary to Bortezomib-Induced Autonomic Neuropathy.硼替佐米诱导的自主神经病变继发肠穿孔
Clin Case Rep. 2025 Apr 1;13(4):e70340. doi: 10.1002/ccr3.70340. eCollection 2025 Apr.
2
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.在初始治疗期间，具有低度周围神经病变的患者接受 BTZ 再治疗的安全性。
Support Care Cancer. 2017 Oct;25(10):3217-3224. doi: 10.1007/s00520-017-3732-6. Epub 2017 Apr 28.
3
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.硼替佐米和长春新碱相关的多发性骨髓瘤患者周围神经病的发病机制：HOVON-65/GMMG-HD4 试验前瞻性数据分析。
Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21.
4
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.多发性骨髓瘤和轻链（AL）淀粉样变性中每周一次皮下注射硼替佐米的神经病变及疗效
PLoS One. 2017 Mar 9;12(3):e0172996. doi: 10.1371/journal.pone.0172996. eCollection 2017.
5
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.伊曲康唑与硼替佐米的药物相互作用：硼替佐米引起的周围神经病和血小板减少症加重。
Pharmacotherapy. 2010 Jul;30(7):661-5. doi: 10.1592/phco.30.7.661.
6
Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.二十二碳六烯酸和α-硫辛酸预防多发性骨髓瘤患者硼替佐米相关周围神经病变：初步数据
Integr Cancer Ther. 2018 Dec;17(4):1115-1124. doi: 10.1177/1534735418803758. Epub 2018 Oct 8.
7
Study on autonomic neuropathy of the digestive system caused by bortezomib in the treatment of multiple myeloma.硼替佐米治疗多发性骨髓瘤引起的消化系统自主神经病变的研究。
Hematology. 2023 Dec;28(1):2210907. doi: 10.1080/16078454.2023.2210907.
8
Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment.神经丝轻链水平表明硼替佐米治疗下存在急性轴索损伤。
J Neurol. 2023 Jun;270(6):2997-3007. doi: 10.1007/s00415-023-11624-2. Epub 2023 Feb 18.
9
Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma.体重指数对新诊断的多发性骨髓瘤患者硼替佐米诱导的周围神经病变发生率的影响。
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):168-173. doi: 10.1016/j.clml.2019.08.012. Epub 2019 Sep 18.
10
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.在复发多发性骨髓瘤的III期APEX试验中硼替佐米对有症状的周围神经病变的可逆性：剂量调整指南的影响
Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.

本文引用的文献

1
The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.硼替佐米诱导周围神经病的毒理学的分子和细胞研究进展。
Biomed Pharmacother. 2021 Oct;142:112068. doi: 10.1016/j.biopha.2021.112068. Epub 2021 Aug 24.
2
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.硼替佐米诱导周围神经病的病理机制。
Int J Mol Sci. 2021 Jan 17;22(2):888. doi: 10.3390/ijms22020888.
3
2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation.2017 WSES 指南：结直肠肿瘤急症处理——梗阻和穿孔。
World J Emerg Surg. 2018 Aug 13;13:36. doi: 10.1186/s13017-018-0192-3. eCollection 2018.
4
Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.降低骨髓瘤合并肾功能损害患者硼替佐米诱导的麻痹性肠梗阻的策略。
BMJ Case Rep. 2016 Nov 29;2016:bcr2016217000. doi: 10.1136/bcr-2016-217000.
5
Bortezomib for the treatment of multiple myeloma.硼替佐米用于治疗多发性骨髓瘤。
Cochrane Database Syst Rev. 2016 Apr 20;4(4):CD010816. doi: 10.1002/14651858.CD010816.pub2.
6
High Incidence of Paralytic Ileus After Bortezomib Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients: Report of 2 Cases.硼替佐米治疗肾移植受者抗体介导排斥反应后麻痹性肠梗阻的高发生率：2例报告
Transplantation. 2015 Nov;99(11):e170-1. doi: 10.1097/TP.0000000000000930.
7
Paralytic ileus following "subcutaneous bortezomib" therapy: focus on the clinical emergency-report of two cases.“皮下注射硼替佐米”治疗后发生的麻痹性肠梗阻：聚焦两例临床急诊报告
Clin Exp Med. 2016 Feb;16(1):99-101. doi: 10.1007/s10238-015-0337-6. Epub 2015 Jan 20.
8
Bortezomib-induced peripheral neurotoxicity: an update.硼替佐米诱导的周围神经毒性：最新进展
Arch Toxicol. 2014 Sep;88(9):1669-79. doi: 10.1007/s00204-014-1316-5. Epub 2014 Jul 29.
9
Multiple significant bortezomib-related toxicities in one patient: case report and literature review.一名患者出现多种与硼替佐米相关的严重毒性反应：病例报告及文献综述
Clin Lymphoma Myeloma. 2009 Jun;9(3):E1-4. doi: 10.3816/CLM.2009.n.051.
10
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.硼替佐米对肾功能损害患者的疗效与安全性：APEX 3期研究结果
Leukemia. 2008 Apr;22(4):842-9. doi: 10.1038/sj.leu.2405087. Epub 2008 Jan 17.